BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Perla A, Fratini L, Cardoso PS, Nör C, Brunetto AT, Brunetto AL, de Farias CB, Jaeger M, Roesler R. Histone Deacetylase Inhibitors in Pediatric Brain Cancers: Biological Activities and Therapeutic Potential. Front Cell Dev Biol 2020;8:546. [PMID: 32754588 DOI: 10.3389/fcell.2020.00546] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Nguyen T, Mueller S, Malbari F. Review: Neurological Complications From Therapies for Pediatric Brain Tumors. Front Oncol 2022;12:853034. [DOI: 10.3389/fonc.2022.853034] [Reference Citation Analysis]
2 Nemes K, Johann PD, Tüchert S, Melchior P, Vokuhl C, Siebert R, Furtwängler R, Frühwald MC. Current and Emerging Therapeutic Approaches for Extracranial Malignant Rhabdoid Tumors. Cancer Manag Res 2022;14:479-98. [PMID: 35173482 DOI: 10.2147/CMAR.S289544] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Tomazou M, Bourdakou MM, Minadakis G, Zachariou M, Oulas A, Karatzas E, Loizidou E, Kakouri A, Christodoulou C, Savva K, Zanti M, Onisiforou A, Afxenti S, Richter J, Christodoulou CG, Kyprianou T, Kolios G, Dietis N, Spyrou GM. Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19. Brief Bioinform 2021:bbab114. [PMID: 34009288 DOI: 10.1093/bib/bbab114] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Servidei T, Meco D, Martini M, Battaglia A, Granitto A, Buzzonetti A, Babini G, Massimi L, Tamburrini G, Scambia G, Ruggiero A, Riccardi R. The BET Inhibitor OTX015 Exhibits In Vitro and In Vivo Antitumor Activity in Pediatric Ependymoma Stem Cell Models. Int J Mol Sci 2021;22:1877. [PMID: 33668642 DOI: 10.3390/ijms22041877] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Kim HY, Choi SA, Koh EJ, Kim KH, Phi JH, Lee JY, Kim SK. Combination Treatment of CI-994 With Etoposide Potentiates Anticancer Effects Through a Topoisomerase II-Dependent Mechanism in Atypical Teratoid/Rhabdoid Tumor (AT/RT). Front Oncol 2021;11:648023. [PMID: 34367950 DOI: 10.3389/fonc.2021.648023] [Reference Citation Analysis]
6 Souza BK, Freire NH, Jaeger M, de Farias CB, Brunetto AL, Brunetto AT, Roesler R. EHMT2/G9a as an Epigenetic Target in Pediatric and Adult Brain Tumors. Int J Mol Sci 2021;22:11292. [PMID: 34681949 DOI: 10.3390/ijms222011292] [Reference Citation Analysis]
7 Curry RN, Glasgow SM. The Role of Neurodevelopmental Pathways in Brain Tumors. Front Cell Dev Biol 2021;9:659055. [PMID: 34012965 DOI: 10.3389/fcell.2021.659055] [Reference Citation Analysis]
8 Tufano M, Cesaro E, Martinelli R, Pacelli R, Romano S, Romano MF. FKBP51 Affects TNF-Related Apoptosis Inducing Ligand Response in Melanoma. Front Cell Dev Biol 2021;9:718947. [PMID: 34589486 DOI: 10.3389/fcell.2021.718947] [Reference Citation Analysis]
9 Shofuda T, Kanemura Y. HDACs and MYC in medulloblastoma: how do HDAC inhibitors control MYC-amplified tumors? Neuro Oncol. 2021;23:173-174. [PMID: 33394043 DOI: 10.1093/neuonc/noaa292] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Moody TW, Lee L, Ramos-Alvarez I, Iordanskaia T, Mantey SA, Jensen RT. Bombesin Receptor Family Activation and CNS/Neural Tumors: Review of Evidence Supporting Possible Role for Novel Targeted Therapy. Front Endocrinol (Lausanne) 2021;12:728088. [PMID: 34539578 DOI: 10.3389/fendo.2021.728088] [Reference Citation Analysis]
11 Abballe L, Miele E. Epigenetic modulators for brain cancer stem cells: Implications for anticancer treatment. World J Stem Cells 2021; 13(7): 670-684 [PMID: 34367473 DOI: 10.4252/wjsc.v13.i7.670] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Shrestha S, Morcavallo A, Gorrini C, Chesler L. Biological Role of MYCN in Medulloblastoma: Novel Therapeutic Opportunities and Challenges Ahead. Front Oncol 2021;11:694320. [PMID: 34195095 DOI: 10.3389/fonc.2021.694320] [Reference Citation Analysis]